Method of treatment of acute hepatosis in cats

FIELD: veterinary medicine.

SUBSTANCE: method comprises administering to the animals in the supine position, in addition to the general course of treatment during 5-7 days of 0.5% novocaine solution, depending on the age at a dose of 1.0-2.0 ml per kg of live body weight with adding 1.0 g of cefazolin in the region of the round ligament of the liver, the administration of novocaine solution with cefazolin. The injections are carried out in a cat in the supine position, at the point at 4.8-5.2 cm cranial to the umbilicus along the sagittal line of the abdomen in the dorsal direction. The puncture is made with the needle to the depth of 0.9-1.1 cm to the feeling of characteristic falling of the needle under the aponeurosis of the rectus abdominis muscle. The preparation solution is administered under pressure.

EFFECT: method is simple to use and highly effective for the treatment of acute hepatosis in cats.

2 tbl, 1 ex


The invention relates to veterinary medicine small animals, in particular for veterinary therapy, and can be used for the treatment of acute hepatosis in cats.

There are several different methods of treatment of laboratory cats. Basically, the treatment aims at the detoxification of the body and strengthening of the regenerative processes in the liver, leading to the restoration of its anatomical structure and functional activity. Apply a decoction of corn stigmas, immortelle, chamomile and other herbs. For normalization of liver function prescribed intravenous solutions of glucose, vitamin C, hexamethylenetetramine. Also used drugs (Essentiale, siripur, LIV-52 and others).

There is a method of treatment of laboratory cats, consisting in the use of the drug "Gepatit". In the preparation includes: phospholipids, methionine, L-ornithine, extract, milk Thistle and grass Immortelle. "Gepatit" is given orally in a dose of 0.3 ml/kg of body weight cats for 30 minutes before feeding. The duration of treatment cats using hepatomata - 30 days (per day used 3 times). The disadvantages of the method include a long course of treatment [1].

There is a method of treatment of laboratory cats with use of the drug "Heptral, which is recommended to be administered intravenously or intramuscularly at a dose of 100-200 mg (per day). Cf is to treatment is 2-3 weeks. The disadvantage of this method is the high cost of the drug and long term treatment [2].

There is a method of treatment of laboratory cats, including pathogenic therapy and the use of the drug "Essentiale Forte H" in injectable form. The drug is administered intravenously in doses of 0.05-0.1 ml per 1 kg of live weight, the treatment is 5-7 days [3, 4]. However, the effectiveness of this method of treatment for acute steatosis is not high enough.

The aim of the invention is to increase the efficiency of treatment of acute hepatosis in cats. This is achieved by the fact that the conventional treatment for steatosis in cats additionally include a single daily administration within 5-7 days 0.5% solution of novocaine with 1.0 g of Cefazolin dose of 1.0-2.0 ml/kg of body weight in the round ligament of the liver. Introduction solution of novocaine with Cefazolin, pre-warmed in a water bath to a temperature 38,0-38,5°C, hold the cat on his back at a point 4.8-5.2 cm more cranial to the umbilicus in the midline of the abdomen in dorsal direction, perpendicular to the anterior abdominal wall make the puncture needle of the average diameter to a depth of 0.9-1.1 cm to the feeling characteristic of dropping the needle under the aponeurosis of the rectus abdominis muscle, then the angle of advancement of the needle is changed to 43-47° in the direction of the liver and under the pressure of the injected drug solution. P is overca the proposed method of treatment of acute hepatosis cats on compliance with the conditions of patentability "novelty" shows what the prior art does not know such technical solutions similar to the claimed invention, including drug infusion in the region of the round ligament of the liver in acute hepatosis in cats.

The proposed method for the treatment of acute hepatosis in cats involves an inventive step, as for the specialist it is not obvious from the prior art. The introduction of a 0.5% solution of novocaine with Cefazolin in the region of the round ligament of the liver in cats when hepatosis so far not been used by specialists in veterinary practice. Our anatomical studies have shown that the round ligament of the liver (umbilical vein) cats over the age of 30 days completes the process of natural anatomical obliteration and 6 months is a connective tissue strand, surrounded by fatty tissue, isolated from the abdominal cavity on all sides parietal peritoneum. This morphological feature when infiltration in the region of the round ligament of the liver contributes to the directed distribution of infusion solution, in the direction of glassonby capsule of the liver, which are approved by the technique of phase-contrast - 30% solution of Urografin.

Novocaine has a complex action on the peripheral nervous system, which includes elements of inhibition and stimulation resulting in improvement of its trophic function. In addition, there is increased blood flow, which in turn contributes to the relief of muscle spasm. Local announcement of the antibiotic Cefazolin suppresses the infection and prevents reproduction of pathogenic microflora, as a function of the reticuloendothelial system when steatosis was reduced.

Novocaine from generating pulses at the end of the sensitive nerves and holding their nerve fibers, reduces the excitability of peripheral cholinergic systems. These factors lead to a rapid decrease of swelling of the liver parenchyma, reduce pain, prevent the development of pathogenic microflora, which contributes to the elimination of symptoms of General intoxication of the organism and to normalize the physiological functions of the body.

The claimed technical solution meets the condition of "industrial applicability"as a method of treatment of acute hepatosis in cats can be used in the practice of veterinary medicine.

The example run. To examine the efficacy of a treatment for acute hepatosis cats on the basis of the veterinary clinic, Dog training Center - Tair (, Zlatoust, Chelyabinsk region) experiment was carried out in 2012-2013. For experiment 20 cats with the observed diagnosis of steatosis were divided into 2 groups of 10 animals each, according to the principle of the steam-analogues. Ucayali the history, gender, age, disease duration, severity of the General condition of the pathology, the severity of clinical symptoms at the time of admission to the clinic.

Animals of the first group was treated by a commonly known method, including complex pathogenetic therapy. This regimen consisted of:

1. Supportive therapy - intravenous infusion:

a). Salt solution (saline, ringer's solution at a rate of 10-20 ml/kg, depending on the degree of dehydration);

b). Nutrient solutions (glucose 5%, Dualit based 6-20 ml/kg depending on the degree of malnutrition).

2. Vitamin therapy (catosal, the rate of 0.5 to 2.5 ml per animal, depending on the individual state, ascorbic acid 0.1 ml).

3. Hepatoprotective therapy (Essentiale Forte H rate of 0.05-0.1 ml / kg of body weight).

4. Antibiotic therapy (amoxicillin is known to be (clamoxyl LA) at a rate of 1 ml per 10 kg of body weight).

5. Antiemetic drugs (if necessary reglan rate of 0.05 ml/kg).

Cats of the second group treatment was supplemented with a daily injection of a 0.5% solution of novocaine at a dose of 1.0 ml/kg body weight with the addition of 1.0 g of Cefazolin, in the region of the round ligament of the liver, within 5-7 days.

The solution was prepared as follows: into a vial containing 1 g of Cefazolin, was added 5 ml of 0.5% solution of novocaine, D. who was idalis complete dissolution of crystals of antibiotic. The calculation of the dose of 0.5% solution of novocaine with dissolved 1 g of Cefazolin was performed: for cats with body weight 1-3 kg dose injection was 2-6 ml, animal with a live weight of 4-8 kg - 6-10 ml. Cats with body weight of more than 8 kg, you must enter a 10 ml Volume of 0.5% solution of novocaine with Cefazolin more than 10 ml type is not recommended because of possible sharp drop in blood pressure and collapse. The dose of 1.0-2.0 ml/kg of body weight is optimal.

Technique of introducing a 0.5% solution of novocaine with Cefazolin consisted of the following stages. Initially, the solution was pre-heated on a water bath until 38-38,5°C. Then the cat on his back on the middle line of the abdomen 5.0 cm above the navel, spent the puncture needle in the dorsal direction to a depth of 1.0 cm to the feeling characteristic of dropping the needle under the aponeurosis of the rectus abdominis muscle. Then using a constant finger pressure on the plunger of the syringe were injected with the drug solution.

For sick animals clinical observation. To assess health took blood samples for laboratory tests on the day of receipt, on the sixth and twelfth days from the start of therapy.

When the clinical observation drew attention to the General condition of the animals, change of appetite, vomiting, change in fluid intake, status is e skin and mucous membranes (yellowness), conducted macroscopic assessment of physiological excrement.

The improvement of the General condition of the animals was ascertained by the reduction or disappearance of icteric staining of the skin and visible mucous membranes, dyspeptic phenomena, the reduction of pain on palpation of the liver, the normalization of the General clinical-physiological state cats, as well as the emergence of positive dynamics in biochemical analysis of blood serum samples.

The recovery is considered full restoration of all physiological functions of organs and systems of the body with regard to laboratory data.

The analysis of the clinical results of treatment of cats the first group showed the following: through the days that have passed since the beginning of the complex conservative therapy, the improvement of the General condition of the animals was not observed, one cat died, the two cats came deterioration of the clinical condition.

On the second day, improvement was observed in three animals, one cat died. On the third day, was seen the following picture: the improvement occurred in two cats, two animals were no positive changes, one animal died.

On the fourth day changes the dynamics of the disease was not observed in any other cats. On the fifth day of conservative treatment, the remaining 7 cats showed a clinical improvement: alive is fair became more active, all disappeared vomiting, decreased daily fluid intake, appetite. Yellowness of the skin and visible mucous continued to persist. Dark urine and agalychnis chair remained.

6-8 day special dynamics of clinical signs were not observed. 9-10 day yellowness of the skin and mucous membranes in all tested cats first group decreased. Urine became lighter, the chair took a normal color.

On 11-12 day, clinical recovery was observed in two cats, five slight yellowness of the skin and mucous membranes. To 15 days, two cats recovered. For 18 days, recovery was observed in the remaining three animals.

Analysis of clinical findings in the treatment of cats second experimental group revealed the following: for the third day, having passed since the beginning of the treatment proposed method of treatment, including conventional therapeutic measures, supplemented by drug infiltration of the round ligament of the liver, improving the General condition occurred in nine animals. They became more active, appetite disappeared thirst at one cat. Specific dynamics of clinical symptoms were not observed.

By the fifth day, the General condition improved in all ten animals, five cats significantly decreased interesest (yellowness) of the visible mucous membranes, has brightened the urine, cal took the usual natural color.

For 7-8 days, three cats recovered, the remaining seven animals yellowness decreased. To 10-12 days, all tested animals a second experimental groups were recovered.

Clinical data of the comparative analysis of results of treatment of cats first and second (experimental) groups with a diagnosis of acute steatosis presented in table No. 1.

Table 1. Comparison of clinical results of treatment in cats
GroupObservation days
1-4 day observation5-8 night surveillance9-12 day observationmore 12 days of observation
The first group5 cats - improvement, 3 cats died, 2 cats - without speakers7 cats were observed clinical improvementthe 2 cats were observed recovery5 cats recovered
The second group9 cats - improvement, 1 cat - unchanged3 cats in what was Zdorovie, 7 cats - observed clinical improvementthe remaining cats recoveredanimal studies have not left

From an analysis of the table shows that in animals treated with additional infusions in the region of the round ligament of the liver, there was no mortality, compared with three cases in the first group. Significantly faster improvement of the General condition of the animals and their recovery: 12 days passed from the beginning of therapy, all cats from the second group recovered, whereas the recovery of the animals of the first group was delayed until 18 days.

These laboratory methods for monitoring sick animals in the dynamics presented in table No. 2.

From the data presented in table No. 2, it is evident that by the sixth day of observation, the cat of the second group of indicators were normalized total protein, glucose, creatinine, lactate dehydrogenase, cholinesterase, indicating a more rapid reparative processes in the liver of these animals. Normalization of parameters of cholinesterase, erythrocyte sedimentation rate, C-reactive protein in animals of the second experimental group indicate a weakening of the inflammatory process in the liver to this day in comparison with indicators of the cats from the first experimental group. By the 12th day of disease on the background of therapy in alive is the shaft of the second experimental group was normalized all the blood counts, and cats first experimental group indicators such as hemoglobin, ESR, total protein, bilirubin, alkaline phosphatase, AST, Alt, cholinesterase remained pathologically altered. Comparative evaluation of the presented data suggests that the functional capacity of the liver in cats the second experimental group recovered significantly faster than animals receiving conventional therapy for acute hepatosis.

Table 2. Data hematological and biochemical studies of blood serum of cats
Metric unitsNORMA1 dayday 6day 12
1 gr.2 gr.1 gr.2 gr.1 gr.2 gr.
1. Hemoglobin, g/l80,0-150,070,065,068,964,570,2±3,2786,6
2. ESR, mm/h0,0 is 13.025,019,018,915,016,8±1,1510,0
3. Total protein, g/l54,0-77,045,050,0to 47.271,0±4,2450,063,3
4. Glucose, mol/l3,3-6,33,22,9±0,893,05,83,04,8
5. Creatinine, mol/l70,0-165,065,370,065,880,0±4,4966,884,0
6. Urea, mmol/l5,4-12,15,8a 4.96,18,95,010,0±0,15
7. Bilirubin, mol/l3,0-12,080,6101,975,921,4±2,3530,213,8
8. Gamma - glutamyltransferase, IU/l1,0-10,07,9±1,166,26,98,4±0,136,99,1±0,15
9. Alkaline phosphatase, IU/l39,0-55,060,055,651,3±3,2955,2to 58.154,0
10. ACT, IU/l9,0-29,0of 58.962,750,138,932,025,0
11. ALT,IU/l19,0-79,0301,2±12,1330,8203,4±11,3108,1120,062,0
12. LDH, IU/l55,0-155,0the amount of 203.9230,1180,8160,9165,0±5,25156,0
Cholinesterase, u/l
14. C-reactive protein, mg/l0,08,0to 12.08,0±1,33,02,50,0
Authentically p<0,05

This manipulation is contraindicated in cats that have not reached the age of 6 months who have not yet completed natural morphogenesis of the round ligament of the liver.

We have developed a method for the treatment of acute hepatosis in cats is an effective, low-cost and simple from the point of view of its technical application. This manipulation allows for local transport of therapeutic substances to the affected organ, thus reducing the cost of drug substances is TBA for additional absorption in the organs of the body, that provides clinical recovery in a short time in the tested animals. A method of treating acute hepatosis in cats recommended widely used in veterinary practice.

The list of references

1. Klimov PV Efficiency new hepatoprotective drug "Gepatit" in the treatment of laboratory dogs and cats / PV Klimov A. Fedosov // Questions of normative-legal regulation in veterinary medicine. - 2011. No. 2. - P.42-44.

2. Gary D. Norsworthy the Feline Patient. Fourth Edition. WileyBlackwell. A. John Willey and Sons, Inc., Publication, 2010. - 1052 p.

3. Clinical gastroenterology animals / I.I. Kalyuzhny, N Barinov, FI fedyk and others; Ed. by I.I. Kalyuzhny. - M.: Colossus, 2010. - 568 S.

4. Handbook of diseases of dogs and cats / Series "veterinary science and animal husbandry". - Rostov n/A.: "Phoenix", 2000. - 352 S.

A method of treating acute hepatosis in cats, including complex pathogenetic therapy, characterized in that the animals in the supine in addition to the General course of treatment for 5-7 days is injected 0.5% solution of novocaine, depending on age at a dose of 1.0-2.0 ml per kg of body weight with the addition of 1.0 g of Cefazolin in the region of the round ligament of the liver, the introduction of a solution of novocaine with Cefazolin hold the cat on his back, at the point 4.8-5.2 cm more cranial to the umbilicus on the sagittal line of the abdomen in dorsal direction is the situation, puncture doing needle to a depth of 0.9-1.1 cm to the feeling characteristic of dropping the needle under the aponeurosis of the rectus abdominis muscle and under the pressure of the injected drug solution.


Same patents:

FIELD: medicine.

SUBSTANCE: invention may be used for prevention of intrahepatic portal hypertension (IPH) in residual tissue of liver in patiens after hepatectomy (HE) of the different volume. That is ensured by an ultrasonography to determine a spleen area to be taken as an original size with underlying standard postoperative therapy in the first postoperative hours. Serotonine adipinate is administered intravenously drop-by-drop in a dose of 5-10 mg an hour with a spleen size monitored periodically. Administering the preparation is terminated if observing a decrease of the spleen area by not less than 10% of the original size.

EFFECT: improved blood circulation in the residual tissue of the liver, prevented IPH decreasing thereby a mortality of the given group of patients.

2 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: method involves a dietary therapy, taking mineral water in an amount of 100-150 ml, 3 times a day and exposure to a physical factor. What is used is the Pevzner's diet No. 5. Karachinskaya chloride-hydrocarbonate sodium gas-free mineral water of total mineralisation up to 3 g/dm3, at a temperature of 38-40°C is taken 30-40 minutes before a meal. The physical factor represents a magnetic laser therapy and an EHF therapy. The contact magnetic laser therapy covers three zones sequentially at a frequency of 5 Hz: an epigastric zone and the right and left upper hypochondria along the midclavicular lines, for 4 minutes for each zone within the course of 10 procedures. The EHF therapy involves combined exposure on two projection zones: in the right hypochondrium and on the sternum generated by a broadband noise emitter at an emission frequency of 40-63 GHz, for 20 minutes, every day within the course of 10 procedures.

EFFECT: method provides more effective rehabilitation treatment following endoscopic cholecystectomy ensured by the early integrated therapeutic exposure.

2 ex, 4 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely gastroenterology, and may be used for treating the patients with the first stage cholelithiasis. That is ensured by administering the preparation Mucofalc 1 sachet 3 times a day for 22-24 weeks.

EFFECT: method enables extending the range of drug preparations having litholytic action in the first stage cholelithiasis with no side effects.

2 tbl, 2 ex

FIELD: chemistry.

SUBSTANCE: composition, which has antiviral activity, includes ammonium glycyrrhizinate, β-cyclodextrin, emulsifier, preservative, lysozyme, polymeric carrier, pH regulator, demineralised water, with specified component ratio. Composition, which has antiviral activity, includes betulinic acid, β-cyclodextrin, emulsifier, preservative, sanguiritrinum, polymeric carrier, suppository base, pH regulator, demineralised water, with specified component ratio.

EFFECT: claimed compositions have expressed antiviral action.

2 cl, 1 tbl, 7 ex

FIELD: food industry.

SUBSTANCE: composition with hepato-protective and immunostimulating properties contains oxygenated dextran with molecular weight equal to 40-70 kDa and a vegetal raw material component chosen from the following group: dry Saint-Mary-thistle fruits extract, dry hill-growing saltwort extract, dry purple echinacea herb extract as well as microcrystalline cellulose as a physiologically acceptable filler, taken in a specified quantity.

EFFECT: hepato-protective and immunostimulating properties enhancement.

1 tbl, 8 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine and cell technologies. What is presented is a cell product containing a population of sub-mandibular salivary duct stem cells described by the phenotype CD49f+/EpCAM+ and changing an expression profile for 1AAT+/PEPCK+/G6P+/TDO+/CYP P4503A13+ after the treatment with valproic acid in the concentration of 0.1-40 mM and cultivation in collagen gel, as well as gaining the capacity to synthetise urea and albumin.

EFFECT: invention allows providing the effective recovery of the insufficient synthetic and detoxification hepatic function accompanying acute and chronic hepatic failure when used both in artificial liver apparatuses, and in the direct transplantation into the affected liver, and can be used for a cell replacement therapy of a wide spectrum of acute and chronic hepatic pathologies, including treating cirrhosis, acute and chronic hepatic failure, as well as for the recovery of the synthetic and detoxification hepatic functions when used as an active cell component in extracorporeal liver apparatuses.

2 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: thoracic epidural analgesia is conducted by puncturing and catheterisation of an epidural space at ThVIII - ThIX before the expiry of 24 hours from the onset of a disease after a moderate intravenous infusion therapy in the amount of 15-20 mg/kg of crystalloid solutions. 20 minutes before an expected endoscopic papillosphincterotomy, a catheter is moved 4-5 cm in a cranial direction. At ThV-ThX, 0.4% naropin 10-12 ml or 0.2% Marcaine 10-12 ml and clonidine 100 mcg are administered through a catheter. That is followed by a pre-medication by administering 0.1% atropine 0.5-1 ml and 0.5% relanium 1-2 ml. Thereafter, the patient is taken to an X-ray operation room to conduct the endoscopic papillosphincterotomy without an endoscopic retrograde cholangiopancreatography with general pancreatic duct stenting. After the operation has been completed, the patient is taken to an intensive care unit wherein an extended epidural analgesia is conducted by administering 0.2% naropin 10-12 ml or 0.15% marcaine 10-12 ml into the epidural space every 4 hours until the patient is taken to a department of surgery.

EFFECT: early intestinal motility recovery, increased pancreatic secretion, prevented spasm of the gastrointestinal sphincter ensured by a pathological complete blockade of sympathetic impulsing.

1 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely hepatology, and may be used for treating patients with hepatic cirrhosis. That is ensured by prescribing Essentiale Forte N as a hepatoprotective agent, detoxification agents, enzymes, diuretics, hemostatic preparations, vitamins B1, B6, C. The probiotic Linex is additionally taken. If observing Child Pugh A and B hepatic cirrhosis, a dosage is 2 capsules 3 times a day. In Child Pugh A disease, the length of the treatment is 6 weeks, while Child Pugh B requires 7 weeks of the treatment. The stage of Child Pugh C hepatic cirrhosis provides taking 3 capsules 3 times a day. The length of the treatment makes 8-9 weeks.

EFFECT: method provides the higher clinical effectiveness ensured by a differentiated approach depending on the stage of hepatic cirrhosis.

2 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely recreation therapy, and may be used for human health improvement. That is ensured by traditional medical examination of the patient. The findings are used to draw up the rehabilitation program including body cleansing, intestine and liver purification, physical exercises. One week before the beginning of the rehabilitation program, the patient starts separate nutrition with preferential vegetable food and dairy products, limited consumption of salt, alcohol and sugar. One day before the rehabilitation program, a fasting day is kept with taking 1% kephir or fresh apple juice. Further, on the first two days of the three-day program or on the first four days of the seven-day program, the body is cleansed by keeping a juice diet. The juice diet contains fresh vegetable and fruit juices, herbal infusions and mineral water. Water is unlimited. On the first day of the cleansing program, the intestine is purified with the preparation Fortrans. Starting from the first day the liver and gall bladder are cleansed with using herbal and saline choleretics for four days of the 7-day program and for two days of the 3-day program. That is combined with paradoxical respiration by Strelnikova's technique and hydrotherapy. Physical exercises involve physical loads on a cardio-vascular machine, one training as prescribed by the doctor - yoga, pilates, chi gong, water aerobics or hypoxi capsule. Therapeutic massage and lymph drainage massage follow. Then body-detox, ozone therapy, collagenarium procedures are performed. Cold training procedures involve Linear Kneipp, saunas, swimming pool, turpentine bathes. Bathing and cold training procedures are followed by pilling and algae wraps. From the 5th day of the 7-day program, or from the 3rd day of the 3-day program, the diet involves water cereals, vegetable and fruit salads, vegetable fast soups.

EFFECT: method provides effective patient's health recovery, namely weight loss, health improvement, blood value normalisation, formation behavioural model of health preservation over a shortest possible period of time.

3 tbl

FIELD: chemistry.

SUBSTANCE: invention relates to novel omega-3 lipid compounds of general formula (I) or to their pharmaceutically acceptable salt, where in formula (I): R1 and R2 are similar or different and can be selected from group of substitutes, consisting of hydrogen atom, hydroxy group, C1-C7alkyl group, halogen atom, C1-C7alkoxy group, C1-C7alkylthio group, C1-C7alkoxycarbonyl group, carboxy group, aminogroup and C1-C7alkylamino group; X represents carboxylic acid or its carbonate, selected from ethylcarboxylate, methylcarboxylate, n-propylcarboxylate, isopropylcarboxylate, n-butylcarboxylate, sec-butylcarboxylate or n-hexylcarboxylate, carboxylic acid in form of triglyceride, diglyceride, 1-monoglyceride or 2-monoglyceride, or carboxamide, selected from primary carboxamide, N-methylcarboxamide, N,N-dimethylcarboxamide, N-ethylcarboxamide or N,N-diethylcarboxamide; and Y stands for C16-C22 alkene with two or more double bonds, which have E- and/or Z-configuration.

EFFECT: described are pharmaceutical and lipid compositions, which contain said compounds, for application as medications, in particular, for treatment and/or prevention of peripheral insulin resistance and/or condition of diabetes, for instance, type 2 diabetes, increased levels of triglycerides and/or levels of non-HDL cholesterol, LDL cholesterol and VLDL cholesterol, hyperlipidemic condition, for instance, hypertriglyceridemia (HTG), obesity or condition of excessive body weight, fatty liver disease, for instance, non-alcoholic fatty liver disease (NAFLD) or inflammatory disease or condition.

60 cl, 3 tbl, 65 ex

FIELD: medicine.

SUBSTANCE: invention refers to fishing industry, and can be used in treating young sturgeon pseudomonosis. A method of treating sturgeon pseudomonosis by individual intramuscular injections of an antibacterial preparation that is presented by cefazolin with a two-stage injection schedule; one day after the first introduction, all subjects are injected with the preparation; if observing a moderate severity, the first introduction includes a dose of 50 mg/kg of body weight, while the second introduction - in the amount of 25 mg/kg of body weight, while the severe disease involves the first introduction in a dose of 100 mg/kg of body weight, and the second introduction in a dose of 50 mg/kg of fish body weight; further the affected fish is fed with a production food with VITAN+ probiotic added; the fish is fed one day and a half later after the beginning of the treatment.

EFFECT: providing fast and complete recovery of surgeons, especially having a severe bacteriosis affection.

2 cl, 1 tbl, 4 ex

FIELD: biotechnologies.

SUBSTANCE: invention refers to a new derivative of β-lactam ceftriaxone antibiotic, which is presented with general formula (I), containing group R1=3-[[(2-methyl-6-oxide-5-oxo-2,5-dihydro-1,2,4-triazine-3-il)sulphanyl]methyl] (a), where R2=sodium, R3=2-amino-3-mercaptopropionate ion -HOOC-CH(NH2)-CH2-S-. Compound is synthesised with interaction of β-lactam ceftriaxone antibiotic with amino acid with cysteine.

EFFECT: derivative of β-lactam ceftriaxone antibiotic, which shows antibacterial properties in relation to bacteria Staphylococcus aureus 25923 and Escherichia coli 25922.

2 cl, 1 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: there are described fine granules containing cefcapene pivoxil hydrochloride wherein cefcapene pivoxil hydrochloride particles are coated with a hydrophobic substance, preferentially hydrogenated oil. The fine granules also contain silicone dioxide and a surfactant having a melting point 30°C or more. Preferentially, as a surfactant, the fine granules contain polyoxyethylene(160)polyoxypropylene(30)glycol.

EFFECT: invention provides improved water affinity of the fine granules, and the improved characteristics of the water suspension of the fine granules of cefcapene pivoxil hydrochloride.

14 cl, 5 dwg, 8 tbl, 9 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: method for preparing a composition for injections containing sodium cevtriaxone and sodium tazobactam involves the following stages: (a) suspension of raw materials, i.e. sodium cevtriaxone, sodium tazobactam, sterilised water for injections, mixed solution of ethyl acetate and isopropyl alcohol, and anhydrous ethanol in mass relation making 3-5:1:2:5:9, with volume relation of ethyl acetate to isopropyl alcohol making 1:2-4; (b) dissolution of sodium cevtriaxone and sodium tazobactam in sterilised water for injections with added activated hydrocarbon and filtration; (c) addition of the mixed solution of ethyl acetate and isopropyl alcohol to the filtrate and agitation of the mixture; addition of a seed crystal of sodium cevtriaxone to the solution for crystallisation initiation; and finally washing of the crystals in anhydrous ethanol and crystal drying; and (d) lyophilisation to form the composition for injections containing sodium cevtriaxone and sodium tazobactam.

EFFECT: composition is characterised by high uniformity, high degree of purity and safety of use.

6 cl, 2 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to surgery, and can be used for treatment of patients with purulent cholangitis. External regulated decompression of bile ducts by means of nasobiliary probe, gallbladder is ablated and drainage in choledoch is installed in patient. After that recanalisation of umbilical vein is performed, umbilical catheter is installed into its lumen. In post-operative period bile ducts are daily washed with drug mixture with antibiotic via nasobiliary probe for 6-8 days. Simultaneously intraportal introduction of antibiotic in dose 1.0 g, dissolved in 250 ml of 0.9% sodium chloride solution is performed via catheter in umbilical vein at rate 20 drops per 1 minute. Antibiotic is selected in accordance with bile microflora sensitivity.

EFFECT: method ensures efficient treatment of said pathology due to simultaneous impact on bile microflora with antibiotic solution both from the side of bile ducts and regionally, from liver side.

1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a pharmaceutical composition applicable as an antimicrobial agent containing at least one antibiotic on the basis of beta-lactame, at least one buffer ingredient, at least one beta-lactamase inhibitor, and at least one antibiotic aminoglycoside. The pharmaceutical composition is presented in the form of a stable precipitation-free system after ultrasound treatment. The invention also refers to a method for preparing said pharmaceutical composition wherein the ingredients of the composition are mixed in the form of a powder for injections which is used to prepare a solution for injections.

EFFECT: preparing the pharmaceutical composition applicable as an antimicrobial agent.

13 cl, 20 tbl, 20 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to method for production of complex immunotropic preparation for animals, including mixing 90 wt parts of 0.2-0.3 % agar suspension, 2.5 wt parts of concentrate of purified polysaccharide complex, 3.5 wt parts (-)2,3,5,6-tetrahydro-6-phenylimidazo-[2,1-b]-thiazole hydrochoride, 0.2 wt parts of formalin and 7.0 wt parts of antibiotic ceftriaxone.

EFFECT: increased non-specific resistance and immunogenesis, prophylactics and treatment of inflammatory processes in animals.

3 tbl, 5 ex

FIELD: medicine.

SUBSTANCE: claimed invention relates to chemical and pharmaceutical industry and deals with composition containing ceftriaxone (usually as sodium ceftriaxone) and sulbactam (usually as sodium sulbactam), which additionally includes gelating preparation of aminocarboxylic acid, for instance ethylenediaminetetraacetic acid (EDTA) or its pharmaceutically acceptable salt, for prevention of beta-lactamase-mediated resistance to antibiotics, intended for injection acceptable for its pharmaceutical application. Said compositions proved useful for intramuscular and intravenous introduction as antibiotics for inpatients with serious infections. It has been found that claimed pharmaceutical compositions usually increase resistance to formation of solid particles in solutions for parenteral introduction. Composition can be made in form, which is preserved in hermetically closed container and is to be restored before application. In addition, invention relates to method of said compositions manufacturing. Claimed is method of treating patient with state or disturbance, in which treatment with application of sodium ceftriaxone and/or sodium subactam is indicated.

EFFECT: composition possesses high stability during storage and does not form solid particles when diluted.

10 cl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to surgery and intensive therapy, and can be used in treating endotoxicoses caused by septic conditions. That is ensured by removal of a destruction area to be thereafter sanitised and drained. It is followed with lymphostimulating therapy by introduction of 0.25% Novocaine 60 ml with dissolved 0.1 g of Lydase and 1.0 ml of Pentoxifylline into the interspinous spaces in number of 1-3 injections. Further, discrete plasmapheresis in amount 400 ml for severe patients and 800 ml in moderate patients is applied in number of 1-8 procedures. The lymphostimulating therapy is alternated every second day with lymphotropic extracorporal pharmacoimmunotherapy with using a medicated mixture prepared by incubation of 40-60 ml of the patient's plasma with received plasma of the patient with Roncoleukin in dosage 500-1 million UN and Cefabol in dosage 1 g for 45 min at 37°C. In peritonitis and peritoneal sepsis, the medicated mixture is introduced in the bolus form in the retroperitoneal fat. The destructive processes in the pleural cavity require introduction of said mixture in the axillary cavity.

EFFECT: method provides endotoxin weakening in the bloodstream, intertissue spaces and cavities due to combined multidirectional local and system effect on the lymphoid system.

3 cl, 8 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: invention concerns medicine, namely to combustiology, intensive and efferent therapy and can be used for treatment of children with a serious thermal trauma. For this purpose anticoagulant therapy is performed to patients for maintenance of hypocoagulation and level of molecules of average mass (AMM) at a wavelength of 254 nanometres are defined in a blood plasma. Treatment is performed at its value from 0.31 to 0.39 standard units, provided that accumulation of AMM prevails in plasma and on erythrocytes, or, at AMM level more than 0.39 standard units, and at AMM accumulation on erythrocytes, in plasma and urine. Infusion of crystalloid solutions in volume of coming hemoexfusion is preliminary performed. Then procedure of discrete centrifugal plasma depletion by unitary hemoexfusion in volume of 10-12% of volume of circulating blood, its gravitational separation and plasma excision is performed. After that 2 ml of the 1% ATP solution and an antibiotic from a number of cephalosporins of III generation in the higher single dose for children in are consistently entered into the received autocell mass.

EFFECT: working out of a way which allows preventing possible complications at treatment of children with the given pathology at the expense of a cryoplasm transfusion exception and other albuminous preparations and also to lower level of an endogenous intoxication, to simplify procedure of extracorporal haemocorrection at conservation of high degree of effect of detoxicating.

2 tbl, 2 ex

FIELD: chemistry, pharmacology.

SUBSTANCE: pharmacological composition for preparing drug forms in form of powder, solution or bandage consists of biocompatible film-generating polymer polyvinylpyrrolidone (Mm 20000), iodine and Novocain, taken in quantities, given in the invention formula. Pharmaceutical composition is intended for processing wound surface and treatment of burns. Composition possesses antiseptic, local anesthetic and wound-healing action.

EFFECT: water-soluble form of medication possesses high anti-burn activity, low cost and long storage term.